Silvia Novello

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer”.

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2302983

N/A

7.3DataRank · unranked

1056 citations

Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Shugeng Gao +14 more

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

New England Journal of Medicine(2023)10.1056/nejmoa2309457

N/A

4.6DataRank · unranked

218 citations

Benjamin Solomon, Herbert H. Loong, Keunchil Park, M. Pérol, Edurne Arriola +19 more

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet(2024)10.1016/s0140-6736(24)01756-2

N/A

3.7DataRank · unranked

262 citations

Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi +91 more

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00061-4

N/A

1.5DataRank · unranked

69 citations

Silvia Novello, Alessandra Bearz, Giovanni Luca Ceresoli, Joachim G.J.V. Aerts, James Spicer +22 more

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

New England Journal of Medicine(2018)10.1056/nejmoa1801005

N/A

1.3DataRank · unranked

6524 citations

Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis +34 more

Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.07.009

N/A

0DataRank · unranked

5 citations

Julia Rotow, Maria E. Arcila, M. Hatton, Lynette M. Sholl, Christian Rolfo +35 more

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100205

N/A

0DataRank · unranked

84 citations

Roy S. Herbst, Gilberto de Castro, Rina Hui, Nir Peled, Dong‐Wan Kim +12 more

Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1316

N/A

0DataRank · unranked

39 citations

Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel T. McManus +16 more

PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance

Therapeutic Advances in Medical Oncology(2025)10.1177/17588359251370510

N/A

0DataRank · unranked

0 citations

Lorenzo Belluomini, Federico Monaca, Michele Simbolo, Antonio Agostini, Andrea Mafficini +18 more